{"nctId":"NCT00000620","briefTitle":"Action to Control Cardiovascular Risk in Diabetes (ACCORD)","startDateStruct":{"date":"1999-09"},"conditions":["Atherosclerosis","Cardiovascular Diseases","Hypercholesterolemia","Hypertension","Diabetes Mellitus, Type 2","Diabetes Mellitus","Coronary Disease"],"count":10251,"armGroups":[{"label":"Glycemia Trial: intensive control","type":"EXPERIMENTAL","interventionNames":["Drug: Anti-hyperglycemic Agents"]},{"label":"Glycemia Trial: standard control","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Anti-hyperglycemic Agents"]},{"label":"BP Trial: intensive control","type":"EXPERIMENTAL","interventionNames":["Drug: Anti-hypertensive Agents"]},{"label":"BP Trial: standard control","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Anti-hypertensive Agents"]},{"label":"Lipid Trial: fenofibrate","type":"EXPERIMENTAL","interventionNames":["Drug: Blinded fenofibrate or placebo plus simvastatin"]},{"label":"Lipid Trial: placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Blinded fenofibrate or placebo plus simvastatin"]}],"interventions":[{"name":"Anti-hyperglycemic Agents","otherNames":["glimepiride (Amaryl)","metformin (Glucophage)","repaglinide (Gluconorm, Prandin)","rosiglitazone (Avandia)","pioglitazone (Actos)","human regular insulin (Novolin ge Toronto)","human NPH (Novolin N)","human mixed (Novolin 70/30)","human isophane (Novolin ge NPH)","human 30/70 (Novolin ge 30/70)","insulin aspart (NovoRapid, NovoLog)","insulin detemir (Levemir)","human regular insulin (Novolin R)","insulin glargine (Lantus)","Acarbose"]},{"name":"Anti-hypertensive Agents","otherNames":["benazepril (Lotensin, Zestril, Altace)","chlorthalidone (Thalitone)","metoprolol (Toprol XL)","diltiazem (Tiazac)","plendil (Felodipine)","terazosin (Hytrin)","candesartan (Atacand)","valsartan (Diovan)","furosemide","reserpine","hydralazine","carvedilol (Coreg)","triamterene / hydrochlorothiazide (Dyazide)","metoprolol / hydrochlorothiazide(Lopressor HCT)","benazepril / hydrochlorothiazide (Lotensin HCT)","lisinopril / hydrochlorothiazide (Zestoretic)","candesartan / hydrochlorothiazide (Atacand HCT)","valsartan / hydrochlorothiazide (Diovan HCT)","amlodipine / benazepril (Lotrel)"]},{"name":"Blinded fenofibrate or placebo plus simvastatin","otherNames":["fenofibrate (Tricor)"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosed with type 2 diabetes mellitus, as determined by the new American Diabetes Association guidelines, which include a fasting plasma glucose level greater than 126 mg/dl (7.0 mmol/l), or a 2-hour postload value in the oral glucose tolerance test of greater than 200 mg/dl, with confirmation by a retest\n* For participants aged 40 years or older, history of CVD (heart attack, stroke, history of coronary revascularization, history of peripheral or carotid revascularization, or demonstrated angina)\n* For participants aged 55 years or older, a history of CVD is not required, but participant must be considered to be at high risk for experiencing a CVD event due to existing CVD, subclinical disease, or 2+ CVD risk factors\n* HbA1c 7.5%-9% (if on more drugs) or 7.5%-11% (if on fewer drugs)","healthyVolunteers":false,"sex":"ALL","minimumAge":"40 Years","maximumAge":"79 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"First Occurrence of a Major Cardiovascular Event (MCE); Specifically Nonfatal Heart Attack, Nonfatal Stroke, or Cardiovascular Death (Measured Throughout the Study) in the Glycemia Trial.","description":"Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. This was the primary outcome measure in all three trials: Glycemia (all participants), Blood Pressure (subgroup of participants not in Lipid Trial), and Lipid (subgroup of participants not in Blood Pressure Trial).\n\nIn the Glycemia Trial, a finding of higher mortality in the intensive arm group led to an early discontinuation of therapy after a mean of 3.5 years of follow-up. Intensive arm participants were transitioned to standard arm strategy over a period of 0.2 year and followed for an additional 1.2 years to the planned end of the Glycemia Trial while participating in one of the other sub-trials (BP or Lipid) to their planned completion.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"503","spread":null},{"groupId":"OG001","value":"543","spread":null}]}]}]},{"type":"SECONDARY","title":"Death From Any Cause in the Glycemia Trial.","description":"Time to death from any cause. Secondary measure for Glycemia Trial.\n\nA finding of higher mortality in the intensive-therapy group led to an early discontinuation of therapy after a mean of 3.5 years of follow-up. Intensive arm participants were transitioned to standard arm strategy over a period of 0.2 year and followed for an additional 1.2 years to the planned end of the Glycemia Trial while participating in one of the other sub-trials (BP or Lipid).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"391","spread":null},{"groupId":"OG001","value":"327","spread":null}]}]}]},{"type":"PRIMARY","title":"First Occurrence of Major Cardiovascular Event (MCE) in the Blood Pressure Trial.","description":"Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. Primary outcome for Blood Pressure Trial.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"208","spread":null},{"groupId":"OG001","value":"237","spread":null}]}]}]},{"type":"SECONDARY","title":"Stroke in the Blood Pressure Trial.","description":"Time to first occurrence of nonfatal or fatal stroke among participants in the BP Trial.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null},{"groupId":"OG001","value":"62","spread":null}]}]}]},{"type":"PRIMARY","title":"First Occurrence of Major Cardiovascular Event (MCE) in the Lipid Trial.","description":"Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death in Lipid Trial participants.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"291","spread":null},{"groupId":"OG001","value":"310","spread":null}]}]}]},{"type":"SECONDARY","title":"First Occurrence of MCE or Revascularization or Hospitalization for Congestive Heart Failure (CHF) in Lipid Trial.","description":"Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, cardiovascular death, revascularization procedure or hospitalization for CHF in Lipid Trial participants.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"641","spread":null},{"groupId":"OG001","value":"667","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":137,"n":5128},"commonTop":[]}}}